Mabion: Continues U.S. vaccine deal-induced rally

Mabion SA

04/03/2021 09:29

** Shares in Polish drug developer Mabion  MABP.WA  surge
24%, extending Wednesday's gains of about 90%  urn:newsml:reuters.com:*:nL5N2L124O 
    ** The stock's rally follows announcement of signing a
framework deal with U.S. vaccine developer Novavax  NVAX.O 
under its COVID-19 vaccine programme  urn:newsml:reuters.com:*:nL2N2L10PM
    ** On Thursday before the bell, Mabion announced start of an
accelerated book building process for a private placement of up
to 2.4 million new shares  urn:newsml:reuters.com:*:nFWN2L20BU
   ** Including today's rise, Mabion stock has gained 250% YTD
and is the best performer on Warsaw mWIG40  .MWIG40  index

 ((Adrianna.Ebert@thomsonreuters.com))